Auro Laboratories Limited Stock Price Today (NSE: AUROLAB)
Fundamental Score
Auro Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Auro Laboratories Limited share price today is ₹234.75, up +1.16% on NSE/BSE as of 7 August 2026. Auro Laboratories Limited (AUROLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹149.48 (Cr). The 52-week high for AUROLAB share price is ₹317.00 and the 52-week low is ₹159.00. At a P/E ratio of 41.07x, AUROLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 8.15% and a debt-to-equity ratio of 1.37.
Auro Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Auro Laboratories Limited share price chart: -10.67% return over the past month. 52-week high ₹317.00, 52-week low ₹159.00.
Auro Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹236.00 | ₹240.90 | ₹235.00 | ₹239.85 | 387.00 (Cr) | |
| ₹232.05 | ₹238.50 | ₹223.10 | ₹235.00 | 2.12K (Cr) | |
| ₹234.75 | ₹239.00 | ₹231.00 | ₹231.10 | 3.79K (Cr) | |
| ₹237.00 | ₹242.85 | ₹232.00 | ₹234.75 | 315.00 (Cr) | |
| ₹238.05 | ₹238.05 | ₹230.00 | ₹235.00 | 3.81K (Cr) | |
| ₹240.00 | ₹240.00 | ₹235.15 | ₹237.00 | 1.17K (Cr) | |
| ₹243.95 | ₹244.00 | ₹237.00 | ₹240.00 | 100.00 (Cr) | |
| ₹241.00 | ₹244.80 | ₹240.00 | ₹243.90 | 88.00 (Cr) | |
| ₹243.10 | ₹246.80 | ₹236.00 | ₹240.50 | 1.66K (Cr) | |
| ₹242.25 | ₹249.85 | ₹237.00 | ₹241.80 | 389.00 (Cr) |
Auro Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹232.05 | ₹240.90 | ₹223.10 | ₹239.85 | +3.36% | |
| ₹259.85 | ₹265.00 | ₹230.00 | ₹231.10 | -11.06% | |
| ₹278.00 | ₹278.00 | ₹240.30 | ₹252.10 | -9.32% | |
| ₹240.00 | ₹285.90 | ₹240.00 | ₹277.50 | +15.63% | |
| ₹265.00 | ₹279.80 | ₹239.00 | ₹239.10 | -9.77% | |
| ₹291.95 | ₹299.00 | ₹252.00 | ₹265.00 | -9.23% | |
| ₹222.05 | ₹317.00 | ₹220.25 | ₹291.95 | +31.48% | |
| ₹244.00 | ₹248.00 | ₹199.95 | ₹226.65 | -7.11% | |
| ₹248.15 | ₹274.00 | ₹236.15 | ₹249.45 | +0.52% | |
| ₹197.00 | ₹269.20 | ₹159.00 | ₹248.15 | +25.96% | |
| ₹245.00 | ₹245.00 | ₹182.30 | ₹193.30 | -21.10% | |
| ₹205.05 | ₹250.00 | ₹192.25 | ₹235.20 | +14.70% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued micro-cap API play; avoid until financials show clear improvement.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The 8% .
CORE STORY (THE REAL GAME)
Auro Laboratories is a micro-cap API manufacturer riding the 'Make in India' pharma wave. The market is betting on continued growth in API exports and import substitution tailwinds.
- API export growth tailwinds
- Import substitution narrative
- Recent price momentum
- New order wins with confirmed ₹ value
- Significant debt reduction
- Clear improvement in OPM and FCF
- Micro-cap liquidity risk
- High debt/equity ratio of 1.01
- OPM and Free Cash Flow data unavailable
FII and DII holdings are negligible [cite: brief]. Promoter holding stable at 52.18% [cite: brief].
Indian pharma sector projected to grow to $130 billion by 2030, but faces global pricing pressures.
No: Free Cash Flow 5Y is ₹None Cr [cite: brief].
3-6 month thesis: Monitor API prices and export data. Look for improvement in OPM and FCF. Avoid until valuation becomes more reasonable.
Primary Thesis Risk
Micro-cap liquidity risk and overvaluation make it vulnerable to sharp correction.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Auro Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Auro Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AUROLAB across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (15.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (174.36%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (32.84%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (52.18%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
11 factors identified
Below-Average Return on Equity (8.15%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.42%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 41.07x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-10.74% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-12.70% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-12.70% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Elevated Debt Levels (D/E: 1.37)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (2.16x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-0.47 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Auro Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Auro Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Auro Laboratories LimitedAuro Laboratori...Selected✓ AUROLAB • 530233 | 34.7/100 | ₹234.75₹235 | ₹149.48₹149.48 | 41.07Average 41.1 Average | 8.15%Poor 8.15% Poor | 9.42%Poor 9.42% Poor | 1.37Average 1.4 Average | -12.70%Poor -12.70% Poor | -10.74%Poor -10.74% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Auro Laboratories Limited Quarterly Performance
Latest quarterly metrics for AUROLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
32.84%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
174.36%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-10.74%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-12.70%
Compounded annual net profit growth over 5 years
Auro Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AUROLAB — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Auro Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Auro Laboratories Limited (AUROLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Auro Laboratories Limited
About AUROLAB (Auro Laboratories Limited)
Auro Laboratories Limited is a dynamic and innovative pharmaceutical company dedicated to the development, manufacture, and distribution of high-quality pharmaceutical products. Co...mmitted to improving global health, Auro Laboratories specializes in crafting a diverse portfolio of active pharmaceutical ingredients (APIs) and advanced drug intermediates. Leveraging cutting-edge research and development capabilities, the company focuses on creating novel formulations and improving existing treatment options. With a robust manufacturing infrastructure, Auro Laboratories adheres to the most stringent international quality standards, ensuring the safety and efficacy of every product. Driven by a team of skilled scientists, engineers, and professionals, Auro Laboratories seeks to address unmet medical needs and make a significant impact on healthcare worldwide. Auro Laboratories Limited is recognized for its strategic approach to pharmaceutical manufacturing, focusing on therapeutic areas with significant patient needs. The company's extensive product range encompasses various therapeutic segments, including treatments for allergies, musculoskeletal disorders, metabolic diseases, and infectious diseases. Auro Laboratories develops and manufactures therapies targeting prevalent conditions such as diabetes, fungal infections, and inflammatory ailments, offering affordable and accessible solutions to healthcare providers and patients alike. Furthermore, the company produces essential supplements, including those addressing iron deficiency and iodine deficiencies, ensuring the availability of vital nutrients in vulnerable populations. Dedicated to expanding its reach and impact, Auro Laboratories continuously invests in new product development and market expansion strategies. Auro Laboratories Limited demonstrates unwavering commitment to sustainable and ethical business practices. The company prioritizes environmental responsibility through implementing eco-friendly manufacturing processes and minimizing its environmental footprint. Auro Laboratories upholds the highest ethical standards in all aspects of its operations, fostering a culture of integrity and transparency. By adhering to rigorous regulatory guidelines and quality control measures, Auro Laboratories ensures that every product meets the highest standards of safety, efficacy, and purity. The company emphasizes building strong relationships with its partners, suppliers, and stakeholders based on trust, collaboration, and mutual respect. Auro Laboratories is dedicated to creating a positive impact on society by providing access to affordable, high-quality medicines and promoting responsible business practices.
Company Details
Key Leadership
AUROLAB Share Price: Frequently Asked Questions
What is the current share price of Auro Laboratories Limited?
Auro Laboratories Limited (AUROLAB) trades at ₹234.75 on NSE and BSE. Market cap ₹149.48 (Cr). Educational data only.
What is the P/E ratio of Auro Laboratories Limited?
Auro Laboratories Limited has a P/E of 41.07x vs industry average 34.89x.
What is the Bull Run score for Auro Laboratories Limited?
Auro Laboratories Limited has a Bull Run score of 34.7/100 based on 25+ financial parameters.
Does Auro Laboratories Limited pay dividends?
Auro Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Auro Laboratories Limited?
Auro Laboratories Limited has ROE of 8.15%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Auro Laboratories Limited?
Auro Laboratories Limited has debt-to-equity of 1.37.
Is Auro Laboratories Limited a good investment?
Bull Run gives Auro Laboratories Limited a score of 34.7/100. This is not investment advice — consult a SEBI-registered advisor.